The rheumatoid arthritis market has exploded in recent years, producing some of big pharma's best-selling blockbuster drugs. AbbVie's Humira hit sales of more than $9 billion to lead the market last year, but competitors from other companies -- such as Johnson & Johnson's Remicade, which hauled in more than $6 billion last year to rank among the top drugs in the industry -- have thrived in a crowded but lucrative immunology field.
Humira faces a patent expiration soon, however, and competition continues to heat up in this space. GlaxoSmithKline is the latest firm to eye the arthritis market after it agreed to a licensing deal with German biotech firm MorphoSys this week for its developmental immunology therapy MOR103. Glaxo's pipeline is sizable and solid, but will this deal brew another blockbuster for the firm's future? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss what you need to know.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article Is This GlaxoSmithKline's Next Big Blockbuster? originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.